Primary |
Urinary Tract Infection |
34.8% |
Hypertension |
12.3% |
Cystitis |
6.7% |
Atrial Fibrillation |
4.8% |
Dyslipidaemia |
3.9% |
Pyrexia |
3.7% |
Prostatitis |
3.5% |
Abdominal Pain |
3.0% |
Prophylaxis |
3.0% |
Depression |
2.8% |
Diarrhoea |
2.6% |
Epilepsy |
2.6% |
Pain |
2.6% |
Bronchitis |
2.4% |
Drug Use For Unknown Indication |
2.4% |
Pyelonephritis |
2.2% |
Anxiety |
1.9% |
Arthralgia |
1.7% |
Dysuria |
1.7% |
Insomnia |
1.5% |
|
Tendonitis |
8.8% |
Drug Exposure During Pregnancy |
8.0% |
Pyrexia |
7.2% |
Tendon Disorder |
7.2% |
Toxic Skin Eruption |
7.2% |
Cytolytic Hepatitis |
6.4% |
Drug Eruption |
6.4% |
International Normalised Ratio Increased |
6.4% |
Rectal Haemorrhage |
4.8% |
Drug Interaction |
4.0% |
Jaundice |
4.0% |
Myalgia |
4.0% |
Paralysis |
4.0% |
Acute Generalised Exanthematous Pustulosis |
3.2% |
Interstitial Lung Disease |
3.2% |
Leukocytoclastic Vasculitis |
3.2% |
Renal Failure Acute |
3.2% |
Rhabdomyolysis |
3.2% |
Vomiting |
3.2% |
Intra-uterine Death |
2.4% |
|
Secondary |
Urinary Tract Infection |
23.9% |
Drug Use For Unknown Indication |
15.4% |
Pyelonephritis |
12.3% |
Product Used For Unknown Indication |
12.2% |
Prophylaxis |
4.1% |
Hypertension |
3.8% |
Epilepsy |
3.4% |
Pyrexia |
2.9% |
Abdominal Pain |
2.6% |
Diabetes Mellitus |
2.3% |
Bronchitis |
2.2% |
Upper Respiratory Tract Inflammation |
2.2% |
Atrial Fibrillation |
1.9% |
Diarrhoea |
1.9% |
Cystitis |
1.8% |
Type 2 Diabetes Mellitus |
1.6% |
Renal Colic |
1.5% |
Bronchopneumopathy |
1.3% |
Depression |
1.3% |
Dyslipidaemia |
1.2% |
|
Tendon Disorder |
51.4% |
Drug Eruption |
5.2% |
Cytolytic Hepatitis |
3.5% |
Thrombocytopenia |
3.5% |
Urticaria |
3.5% |
Pyrexia |
2.9% |
Renal Failure Acute |
2.9% |
Vomiting |
2.9% |
Condition Aggravated |
2.3% |
Haemolytic Anaemia |
2.3% |
Leukopenia |
2.3% |
Pancreatitis Acute |
2.3% |
Urinary Tract Infection |
2.3% |
Vulvovaginal Dryness |
2.3% |
Hyponatraemia |
1.7% |
Myalgia |
1.7% |
Pancytopenia |
1.7% |
Pseudomembranous Colitis |
1.7% |
Red Blood Cell Count Decreased |
1.7% |
Rhabdomyolysis |
1.7% |
|
Concomitant |
Drug Use For Unknown Indication |
32.7% |
Product Used For Unknown Indication |
11.0% |
Urinary Tract Infection |
9.2% |
Hypertension |
8.5% |
Hepatitis C |
6.2% |
Rheumatoid Arthritis |
4.8% |
Diabetes Mellitus |
2.9% |
Epilepsy |
2.6% |
Prophylaxis |
2.6% |
Depression |
2.5% |
Anaemia |
2.2% |
Unevaluable Event |
2.1% |
Ascites |
1.8% |
Gastrooesophageal Reflux Disease |
1.8% |
Multiple Myeloma |
1.6% |
Osteoporosis |
1.6% |
Pain |
1.6% |
Cystitis |
1.5% |
Sleep Disorder |
1.5% |
Essential Hypertension |
1.3% |
|
Stevens-johnson Syndrome |
9.9% |
Tremor |
7.7% |
Vomiting |
7.7% |
Renal Failure |
6.6% |
Renal Impairment |
6.6% |
Neutropenia |
5.5% |
Upper Limb Fracture |
5.5% |
White Blood Cell Count Decreased |
5.5% |
Anaemia |
4.4% |
Portal Vein Thrombosis |
4.4% |
Respiratory Failure |
4.4% |
Toxic Skin Eruption |
4.4% |
Visual Impairment |
4.4% |
Deep Vein Thrombosis |
3.3% |
Hepatic Encephalopathy |
3.3% |
Jaundice |
3.3% |
Oedema Peripheral |
3.3% |
Pruritus |
3.3% |
Pulmonary Embolism |
3.3% |
Pyrexia |
3.3% |
|
Interacting |
Drug Use For Unknown Indication |
34.8% |
Urinary Tract Infection |
13.0% |
Atrial Fibrillation |
8.7% |
Chronic Myeloid Leukaemia |
8.7% |
Depression |
8.7% |
Abdominal Pain Upper |
4.3% |
Cystitis |
4.3% |
Hiatus Hernia |
4.3% |
Multiple Sclerosis |
4.3% |
Myocardial Ischaemia |
4.3% |
Pyelonephritis |
4.3% |
|
International Normalised Ratio Increased |
22.2% |
Urinary Tract Infection |
22.2% |
Drug Interaction |
11.1% |
Fall |
11.1% |
Liver Function Test Abnormal |
11.1% |
Rhabdomyolysis |
11.1% |
Vomiting |
11.1% |
|